Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 183

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 183
---
 As such, this transaction will be accounted for as a capital transaction. Accordingly, the financial statements of Longevity
will represent the continuation of the financial statements of Cerevast with the merger treated as the equivalent of Cerevast issuing
stock for the net assets of Longevity, accompanied by a recapitalization.

In connection
with the acquisition of Aegeria, substantially all the fair value is included in in process research and development (“IPR&D”)
and, as such, the acquisition will be treated as an asset acquisition. Aegeria’s assets and liabilities will be measured and recognized
at their relative fair values as of the transaction date with any value associated with IPR&D being expensed as there is no alternative
future use. The fair value of assets and liabilities of Aegeria will be combined with the assets, liabilities and results of operations
of Longevity after the consummation of the Merger. The reported consolidated financial condition and results of operations of Longevity
after completion of the Target Acquisitions will reflect these fair values.

Expected Accounting Treatment
of the Business Combination among FutureTech and combined Longevity

The Business
Combination is expected to be accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting,
FutureTech is expected to be treated as the “acquired” company for financial reporting purposes. Accordingly, for accounting
purposes, the financial statements of FutureTech will represent a continuation of the financial statements of the combined group of Longevity
with the Business Combination treated as the equivalent of Longevity issuing stock for the net assets of FutureTech, accompanied by a
recapitalization. The net assets of FutureTech will be stated at historical cost, with no goodwill or other intangible assets recorded.
FutureTech’s currently outstanding warrants are expected to remain equity-classified subsequent to the completion of the Business
Combination based on an evaluation of whether the terms of the Business Combination might impact the historical accounting for the warrants.
Following the Merger, Longevity will be a subsidiary of FutureTech. At Closing, FutureTech will change its name to Longevity Biomedical,
Inc., and its common stock is expected to list on Nasdaq under the ticker symbol “LBIO”. Operations prior to the Business
Combination will be those of Longevity in future reports of FuureTech.

Longevity is the accounting acquirer
based on evaluation of the following facts and circumstances:

| ● | Majority of the board of directors will